These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 29270111)

  • 21. Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA).
    Šoltić D; Bowerman M; Stock J; Shorrock HK; Gillingwater TH; Fuller HR
    Brain Sci; 2018 Dec; 8(12):. PubMed ID: 30518112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship of spinal muscular atrophy to motor neuron disease: investigation of SMN and NAIP gene deletions in sporadic and familial ALS.
    Orrell RW; Habgood JJ; de Belleroche JS; Lane RJ
    J Neurol Sci; 1997 Jan; 145(1):55-61. PubMed ID: 9073029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.
    Jablonka S; Hennlein L; Sendtner M
    Neurol Res Pract; 2022 Jan; 4(1):2. PubMed ID: 34983696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in therapy for spinal muscular atrophy: promises and challenges.
    Groen EJN; Talbot K; Gillingwater TH
    Nat Rev Neurol; 2018 Apr; 14(4):214-224. PubMed ID: 29422644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
    Hoy SM
    CNS Drugs; 2018 Jul; 32(7):689-696. PubMed ID: 30027400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The intriguing case of motor neuron disease: ALS and SMA come closer.
    Achsel T; Barabino S; Cozzolino M; Carrì MT
    Biochem Soc Trans; 2013 Dec; 41(6):1593-7. PubMed ID: 24256260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
    Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges.
    Messina S; Sframeli M
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32668756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy.
    O'Connor DM; Boulis NM
    Neurosci Lett; 2012 Oct; 527(2):78-84. PubMed ID: 22579818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology.
    Comley LH; Nijssen J; Frost-Nylen J; Hedlund E
    J Comp Neurol; 2016 May; 524(7):1424-42. PubMed ID: 26502195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy.
    Bogdanik LP; Osborne MA; Davis C; Martin WP; Austin A; Rigo F; Bennett CF; Lutz CM
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):E5863-72. PubMed ID: 26460027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.
    Veldink JH; Kalmijn S; Van der Hout AH; Lemmink HH; Groeneveld GJ; Lummen C; Scheffer H; Wokke JH; Van den Berg LH
    Neurology; 2005 Sep; 65(6):820-5. PubMed ID: 16093455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis.
    Osmanovic A; Wieselmann G; Mix L; Siegler HA; Kumpe M; Ranxha G; Wurster CD; Steinke A; Ludolph AC; Kopp B; Lulé D; Petri S; Schreiber-Katz O
    Brain Sci; 2020 Dec; 11(1):. PubMed ID: 33374658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Motor neuron diseases. Present].
    Pou A
    Neurologia; 1996 Dec; 11 Suppl 5():1-6. PubMed ID: 9044569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
    Gidaro T; Servais L
    Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deletions causing spinal muscular atrophy do not predispose to amyotrophic lateral sclerosis.
    Parboosingh JS; Meininger V; McKenna-Yasek D; Brown RH; Rouleau GA
    Arch Neurol; 1999 Jun; 56(6):710-2. PubMed ID: 10369311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F
    Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
    Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
    PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.